Top

Breast Cancer Research and Treatment

Published in:

01-05-2010 | Letter to the Editor

Some common mutations of RAD50 and NBS1 in western populations do not contribute significantly to Chinese non-BRCA1/2 hereditary breast cancer

Authors: A-Yong Cao, Zhen Hu, Wen-Jin Yin, Wei Jin, Zhi-Ming Shao

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Excerpt

To the editor …

Li WF, Hu Z, Rao NY et al (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 110:99–109CrossRefPubMed

D’Amours D, Jackson SP (2002) The Mre11 complex: at the crossroads of DNA repair and checkpoint signalling. Nat Rev Mol Cell Biol 3:317–327CrossRefPubMed

Heikkinen K, Rapakko K, Karppinen SM et al (2006) RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 27:1593–1599CrossRefPubMed

Cao AY, Jin W, Shi PC et al (2009) Identification and characterization of two novel germ line p53 mutations in the non-LFS/non-LFL breast cancer families in Chinese population. Breast Cancer Res Treat. doi:10.1007/s10549-009-0349-6

Bogdanova N, Schurmann P, Waltes R et al (2008) NBS1 variant I171 V and breast cancer risk. Breast Cancer Res Treat 112:75–79CrossRefPubMed

Pardini B, Naccarati A, Polakova V et al (2009) NBN 657del5 heterozygous mutations and colorectal cancer risk in the Czech Republic. Mutat Res 666:64–67PubMed

Tommiska J, Seal S, Renwick A et al (2006) Evaluation of RAD50 in familial breast cancer predisposition. Int J Cancer 118:2911–2916CrossRefPubMed

Uhrhammer N, Delort L, Bignon YJ (2009) Rad50 c.687delT does not contribute significantly to familial breast cancer in a French population. Cancer Epidemiol Biomarkers Prev 18:684–685CrossRefPubMed

Seemanova E (1990) An increased risk for malignant neoplasms in heterozygotes for a syndrome of microcephaly, normal intelligence, growth retardation, remarkable facies, immunodeficiency and chromosomal instability. Mutat Res 238:321–324PubMed

10.

Steffen J, Varon R, Mosor M et al (2004) Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. Int J Cancer 111:67–71CrossRefPubMed

11.

Buslov KG, Iyevleva AG, Chekmariova EV et al (2005) NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia. Int J Cancer 114:585–589CrossRefPubMed

12.

Zhang Y, Zhou J, Lim CU (2006) The role of NBS1 in DNA double strand break repair, telomere stability, and cell cycle checkpoint control. Cell Res 16:45–54CrossRefPubMed

13.

Roznowski K, Januszkiewicz-Lewandowska D, Mosor M et al (2008) I171 V germline mutation in the NBS1 gene significantly increases risk of breast cancer. Breast Cancer Res Treat 110:343–348CrossRefPubMed

14.

Bogdanova N, Feshchenko S, Schurmann P et al (2008) Nijmegen breakage syndrome mutations and risk of breast cancer. Int J Cancer 122:802–806CrossRefPubMed

15.

Song CG, Hu Z, Yuan WT et al (2006) CHEK2 c. 1100delC may not contribute to genetic background of hereditary breast cancer from Shanghai of China. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 23:443–445

Title: Some common mutations of RAD50 and NBS1 in western populations do not contribute significantly to Chinese non-BRCA1/2 hereditary breast cancer
Authors: A-Yong Cao
Zhen Hu
Wen-Jin Yin
Wei Jin
Zhi-Ming Shao
Publication date: 01-05-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0629-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2010

Breast cancer risk in women who fulfill high-risk criteria: at what age should surveillance start?

Broad BRCA1 and BRCA2 mutational spectrum and high incidence of recurrent and novel mutations in the eastern Spain population

Estrogen receptor regulation: don’t forget translation

Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198

A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells

Sensitivity analyses including and excluding the HWE-violating studies are required for meta-analyses of genetic association studies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer